Merit Medical Systems has signed a $22 million agreement to acquire the C2 CryoBalloon device and related technology from PENTAX of America, expanding its footprint in gastroenterology. The device is used to treat Barrett’s esophagus, gastric antral vascular ectasia (GAVE), GERD-related disorders, and other GI tissue conditions through targeted cryoablation.
- Market Context: The U.S. gastroenterology device market is projected to reach $20.97B by 2033.
- Revenue Impact: Merit expects the C2 CryoBalloon to add $6–8M in GI revenue in 2026.
- Strategic Fit: The technology will integrate into Merit’s endoscopy portfolio, complementing its recent acquisitions (e.g., Biolife Delaware for $120M, adding StatSeal/WoundSeal products).
- Technology Advantage: The CryoBalloon precisely freezes and destroys abnormal cells while sparing surrounding tissue integrity.
- Operations: Merit plans to transfer device manufacturing to its South Jordan, Utah facility and absorb certain PENTAX employees.